Independent publication. We may earn a commission when you use certain links. Learn more.
WWeight Care Compass Explore ↓
Wave 1

Best Online GLP-1 Providers: What to Compare Before Choosing

A provider-selection framework for online GLP-1 programs, including HealthRx, Mochi, Henry Meds, Ro and Hims.

Reviewed August 19, 2026 · Independent editorial content

There is no single 'best' online GLP-1 provider for every patient. Programs differ in medication type, insurance strategy, membership fees, compounding model, provider access and commitment length. The useful question is which model fits your treatment and payment preferences.

Five providers to put on the comparison list

HealthRx emphasizes bundled cash-pay plans for compounded semaglutide and tirzepatide. Mochi advertises both compounded and branded medication pathways. Henry Meds offers cash-pay weight-management programs with multiple medication formats. Ro focuses heavily on access to FDA-approved GLP-1s and insurance navigation. Hims offers a membership-based weight-loss service with medication options that vary over time.

Compare the program before the headline price

Our HealthRx lens

HealthRx is most naturally compared with cash-pay programs because its core proposition is transparent bundled pricing. Someone with strong insurance coverage may find a brand-focused provider more relevant even if the membership fee is separate.

Safety and regulatory context

FDA states that compounded drugs are not FDA-approved and are not reviewed before marketing for safety, effectiveness or quality. FDA has also warned telehealth companies about false or misleading claims concerning compounded GLP-1 products. That makes pharmacy transparency and accurate labeling important comparison factors—not footnotes.

How to choose

Shortlist two or three services based on medication pathway and payment model, then verify current pricing, pharmacy information, clinician access and cancellation terms directly with each provider before paying.

Sources & verification

We use primary sources for time-sensitive commercial and regulatory claims.

Last reviewed: August 19, 2026